A Phase 1, Single- and Multiple-Dose, Double-Blind, Randomized, Placebo-Controlled, Dose-Escalating Study to Assess the Safety, Tolerability, and Pharmacokinetics of NLY01, a PEGylated Exenatide, Administered by Subcutaneous Injection in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 03 Oct 2018
At a glance
- Drugs NLY 01
- Indications Alzheimer's disease; Parkinson's disease
- Focus Adverse reactions; First in man
- Sponsors Neuraly
- 21 Sep 2018 Status changed from not yet recruiting to recruiting.
- 13 Sep 2018 Status changed from planning to not yet recruiting.
- 24 Jul 2018 New trial record